The US Oncology Research Network is currently recruiting patients with advanced bladder/urothelial carcinoma who have progressed despite prior chemotherapy for a phase 2 study of lapatinib, an oral drug which inhibits two proteins (EGFR and HER-2) that may play a key role in the growth and spread of urothelial cancers. This trial employs a novel design in which patients with urothelial cancer (and other solid tumors) have their prior biopsy or surgical specimens sent to a central lab to determine if the Her-2 protein is over-expressed. If the protein is over-expressed, then patients are offered enrollment on the clinical trial. This design attempts to select patients who are most likely to benefit from the treatment with the hopes of advancing “personalized” medicine.
In order to be eligible for this study, patients must have metastatic urothelial carcinoma that has progressed despite prior chemotherapy and must have adequate organ function. A signed consent form is required before participation in the study is allowed.
This study is being offered at several sites throughout the United States. For more information about this trial, contact Dr. Galsky at 702-952-3400 or This email address is being protected from spambots. You need JavaScript enabled to view it..
